S'abonner

Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery - 18/08/11

Doi : 10.1016/j.ahj.2006.07.009 
Mary A.M. Rogers, PhD, MS a, d, , Neil Blumberg, MD b, Sanjay K. Saint, MD, MPH a, d, e, Catherine Kim, MD, MPH a, f, Brahmajee K. Nallamothu, MD, MPH c, d, e, Kenneth M. Langa, MD, PhD a, d, e, g, h, i
a Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 
b Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 
c Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 
d Patient Safety Enhancement Program, University of Michigan Health System Ann Arbor, MI 
e Health Services Research and Development Center of Excellence, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI 
f Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI 
g Institute for Social Research, University of Michigan, Ann Arbor, MI 
h SGIM-Hartford Collaborative Center for Research and Education in the Care of Older Adults, University of Michigan Medical School, Ann Arbor, MI 
i Institute of Gerontology, University of Michigan, Ann Arbor, MI 

Reprint requests: Mary A.M. Rogers, PhD, Department of Internal Medicine, University of Michigan, 300 North Ingalls, Suite 7E07, Ann Arbor, MI 48109-0429.

Résumé

Background

Postoperative mortality is greater in women than men after coronary artery bypass graft surgery. Because allogeneic blood transfusions are more common in women and have been associated with immunomodulation, the impact of transfusion on sex differences in infection and mortality was examined.

Methods

A cohort study was conducted using Michigan Medicare beneficiaries who had undergone coronary artery bypass graft surgery. Information was used regarding allogeneic blood transfusion, infection, and mortality within the 100-day period after surgery.

Results

Blood transfusions were more common in women than in men (88.2%, 95% CI 87.1%-89.2% vs 66.7%, 95% CI 65.5%-67.9%). Patients who received transfused blood were more likely to have an infection than patients who did not (14.6%, 95% CI 13.8%-15.5% vs 4.9%, 95% CI 4.1%-5.9%). There was a dose-response relationship between the number of units of whole blood or packed red cells received and the prevalence of infection (P = .035). The unadjusted risk of mortality attributable to female sex was 13.9% (95% CI 8.1%-19.6%), but was no longer statistically significant when adjusted for blood transfusion (population attributable risk 0.6%, 95% CI −6.0% to 6.6%). Patients who received a transfusion were 5.6 times as likely to die within 100 days after surgery as those who did not receive a transfusion (95% CI 3.7-8.6).

Conclusion

The increased risk of mortality in women after bypass surgery may be explained by transfusion-related immunosuppression.

Le texte complet de cet article est disponible en PDF.

Plan


 This study was supported by AHRQ award P20-HS11540, NIA award K08 AG19180, NIDDK grant 1R21 DK067451-01A1, Department of Veterans Affairs Health Services Research and Development Office award RCD-00-006, grant 2002-0013 from The John A. Hartford Foundation, New York, NY, and a Paul Beeson Physician Faculty Scholars in Aging Research award.


© 2006  Mosby, Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 152 - N° 6

P. 1028-1034 - décembre 2006 Retour au numéro
Article précédent Article précédent
  • Assessment of and physician response to glycemic control in diabetic patients presenting with an acute coronary syndrome
  • Darcy L. Green Conaway, Jonathan R. Enriquez, Jaime E. Barberena, Philip G. Jones, James H. O'Keefe, John A. Spertus
| Article suivant Article suivant
  • Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States
  • Jing Fang, George A. Mensah, Michael H. Alderman, Janet B. Croft

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.